DRP1-mediated mitochondrial fission integrates growth hormone signaling with metabolic and stress adaptation in triple-negative breast cancer

This study demonstrates that growth hormone drives triple-negative breast cancer progression by activating DRP1-mediated mitochondrial fission, which is essential for linking metabolic reprogramming toward glycolysis with cell proliferation and the modulation of the inflammatory tumor microenvironment.

The Gist

The Big Picture: A "Growth Hormone" Cheat Code for Cancer

Imagine a triple-negative breast cancer (TNBC) cell as a rogue construction crew building a chaotic, illegal skyscraper (the tumor). Usually, these crews are smart but limited by their resources and the rules of the city (the body's environment).

This study discovered that Growth Hormone (GH) acts like a super-caffeinated energy drink for this construction crew. It doesn't just make them work faster; it fundamentally changes how they build, allowing them to survive in terrible conditions (like low oxygen) and recruit the local neighborhood (the immune system) to help them instead of stopping them.

The secret weapon? A tiny cellular machine called DRP1, which acts like a pair of molecular scissors.

---

The Story in Four Acts

1. The Energy Switch: From "Clean Power" to "Dirty Fuel"

Normally, healthy cells run on a clean, efficient engine called mitochondria (the power plants). They burn fuel with oxygen to create energy.

• What the cancer cells do: When Growth Hormone hits the cancer cell, it tells the mitochondria to stop being efficient and start acting like a smokestack. The cell switches to "glycolysis" (burning sugar without oxygen).
• The Analogy: Think of a car engine. A normal car uses a clean hybrid engine. The cancer cell, under the influence of GH, switches to a loud, smoky, old diesel engine that burns fuel incredibly fast to get a quick burst of speed, even though it's messy.
• The Result: The cancer cells grow faster and produce more "exhaust" (lactate), but they don't actually need more oxygen to do it.

2. The Scissors (DRP1): The Key to the Switch

Here is the most important part of the study. To make this switch to the "dirty diesel" engine, the cell needs to cut its power plants into tiny pieces.

• The Mechanism: The cell uses a protein called DRP1 (Dynamin-related protein 1). Imagine DRP1 as a pair of scissors that snips long, connected power plants into many small, fragmented pieces.
• The Discovery: The study found that Growth Hormone turns the "scissors" on. It makes the cell cut its mitochondria into tiny fragments.
• The Proof: When the researchers used a drug (Mdivi-1) to jam the scissors, the cancer cells couldn't switch to the fast, dirty fuel mode. Even with the Growth Hormone energy drink, the cancer cells couldn't grow fast because they couldn't cut their power plants.
• The Lesson: The scissors (DRP1) are the bridge. Without them, the Growth Hormone signal is useless.

3. Surviving the "Oxygen Starvation" (Hypoxia)

Tumors often grow so big that the center runs out of oxygen (hypoxia). Usually, this kills cells.

• The Analogy: Imagine a construction crew working in a basement with no windows. Most crews would collapse.
• The Result: The Growth Hormone-treated cancer cells, with their "scissors" active, were able to survive and even thrive in this oxygen-starved basement. They reprogrammed their metabolism to keep going, while the control cells struggled.

4. Recruiting the Neighborhood (The Microenvironment)

Finally, the study looked at what happens when these cancer cells are placed inside a living organism (using zebrafish as a model).

• The Analogy: The cancer cells aren't just building a skyscraper; they are also sending out flares to the neighborhood.
• The Result: The Growth Hormone-treated cells released signals that told the body's immune system, "Hey, we need inflammation here!" This created a pro-inflammatory environment (a neighborhood that is angry and chaotic).
• Why it matters: This inflammation actually helps the tumor grow and spread, rather than fighting it. The cancer hijacked the body's defense system to build its own fortress.

---

Why This Matters (The "So What?")

This research connects three dots that scientists knew existed but didn't know how they fit together:

1. Growth Hormone (often linked to cancer risk).
2. Mitochondrial Scissors (DRP1).
3. Cancer Metabolism (how cancer eats and grows).

The Takeaway:
Growth Hormone doesn't just tell cancer to "grow." It tells the cancer to cut its power plants (via DRP1). This cutting forces the cancer to switch to a fast, messy fuel source that allows it to grow rapidly, survive without oxygen, and trick the immune system into helping it.

The Future:
If we can find a way to jam the scissors (block DRP1) or stop the Growth Hormone signal, we might be able to starve these aggressive cancer cells of their ability to adapt. It's like taking away the construction crew's ability to switch to diesel fuel; they might be forced to stop building.

Summary in One Sentence

Growth Hormone helps triple-negative breast cancer grow by activating a pair of molecular scissors (DRP1) that chop up the cell's power plants, forcing the cancer to switch to a fast, messy fuel source that lets it survive in tough conditions and trick the body's immune system into helping it.

Technical Summary

1. Problem Statement

Triple-negative breast cancer (TNBC) relies heavily on metabolic plasticity to survive and proliferate under diverse microenvironmental stresses, such as hypoxia and nutrient deprivation. While Growth Hormone (GH) signaling is known to be associated with breast cancer progression, the specific molecular mechanisms by which GH integrates with mitochondrial dynamics (fusion/fission) to rewire tumor metabolism and stress responses remain unclear. Specifically, it is unknown how GH signaling coordinates the shift toward glycolysis (the Warburg effect) and how mitochondrial remodeling influences the coupling of metabolic reprogramming to cell-cycle progression and the tumor microenvironment (TME).

2. Methodology

The study utilized the MDA-MB-231 TNBC cell line across a multi-dimensional experimental framework:

• In Vitro Models:
  • 2D Monolayers: Standard culture conditions treated with recombinant human GH (rhGH, 100 ng/mL) for up to 6 days.
  • 3D Spheroids: Cells cultured in ultra-low attachment plates to form spheroids, mimicking solid tumor architecture with hypoxic cores.
  • Hypoxia: Cells exposed to 1% O₂ to simulate the tumor core environment.
  • Pharmacological Inhibition: Use of Mdivi-1 (15 µM), a specific inhibitor of mitochondrial fission (targeting DRP1), to dissect the role of mitochondrial dynamics.
• In Vivo Models:
  • Zebrafish Xenografts: MDA-MB-231 cells (2D and 3D derived) were injected into adult zebrafish (AB wild-type and Tg(GH:GFP) transgenic lines) to assess tumor engraftment and host inflammatory response.
• Analytical Techniques:
  • Metabolic Flux: Seahorse XF Analyzer to measure Oxygen Consumption Rate (OCR) and Extracellular Acidification Rate (ECAR).
  • Metabolite Quantification: Glucose consumption and lactate production assays.
  • Molecular Biology: Western blotting (DRP1, pDRP1, MFN2, p53, HIF1A), qRT-PCR (DNM1L, MFN2, TP53, HIF1A), and immunofluorescence/confocal microscopy for mitochondrial morphology.
  • Bioinformatics: Integration of public transcriptomic datasets (GSE36295, GSE38959, GSE250157) to validate findings in human TNBC patient samples.

3. Key Contributions

• Mechanistic Link: Established a direct causal link between GH signaling and DRP1-dependent mitochondrial fission in TNBC.
• Metabolic Uncoupling: Demonstrated that mitochondrial fission is a prerequisite for coupling GH-induced glycolytic flux to cell proliferation; inhibiting fission uncouples these processes.
• Stress Adaptation: Revealed that the GH-DRP1 axis modulates stress-response pathways (TP53 and HIF1A) and shapes a pro-inflammatory tumor microenvironment.
• Model Validation: Validated findings across 2D, 3D, hypoxic, and in vivo models, showing that 3D spheroids accelerate the metabolic response to GH compared to 2D cultures.

4. Key Results

A. GH Promotes Proliferation and Mitochondrial Remodeling

• Proliferation: GH treatment significantly increased MDA-MB-231 cell number and total protein content.
• Mitochondrial Dynamics: GH increased mitochondrial mass and induced fragmentation (fission). This was evidenced by increased levels of DRP1 and its active phosphorylated form (pDRP1), alongside a reduction in the fusion protein MFN2 at the transcriptional level.
• Stress Markers: GH treatment led to a time-dependent regulation of TP53 and HIF1A, suggesting an adaptive response to metabolic stress.

B. Metabolic Reprogramming: Glycolysis over Oxidative Phosphorylation

• Glycolytic Shift: GH-treated cells exhibited a marked increase in ECAR (glycolytic rate) and lactate production, indicating a shift toward glycolysis.
• OCR Stability: Despite increased mitochondrial mass, OCR (oxidative phosphorylation) remained unchanged when normalized to protein content. This suggests GH drives a "regulated Warburg phenotype" where mitochondria support biosynthesis and signaling rather than maximal ATP production via respiration.
• DRP1 Dependence: Treatment with Mdivi-1 (DRP1 inhibitor) reversed GH-induced mitochondrial fragmentation and altered glycolytic parameters. Crucially, Mdivi-1 uncoupled GH-induced glycolysis from proliferation, proving that fission is required to translate metabolic changes into cell growth.

C. Modulation of Stress Signaling and Hypoxia

• Protein Regulation: Mdivi-1 treatment reversed GH-induced changes in acetyl-p53 and HIF1A levels, indicating that mitochondrial dynamics sit upstream of these stress regulators.
• Hypoxic Response: Under hypoxia (1% O₂), GH maintained its ability to increase cell number and glucose consumption but paradoxically reduced lactate accumulation compared to hypoxic controls. This suggests GH redirects carbon flux to limit acidification under stress.
• 3D Spheroids: In 3D models, GH effects (increased protein, glucose consumption, pDRP1) were observed earlier (day 4) than in 2D (day 6), highlighting the importance of tumor architecture.

D. In Vivo and Microenvironment Effects

• Tumor Engraftment: GH-conditioned cells (especially from 3D spheroids) showed enhanced engraftment and growth in zebrafish xenografts.
• Inflammatory Niche: GH-exposed tumors upregulated host pro-inflammatory genes (cxcr4b, il8, il12), suggesting GH-driven mitochondrial remodeling fosters a pro-inflammatory TME conducive to tumor progression.

E. Clinical Correlation

• Transcriptomic analysis of human TNBC datasets confirmed the conservation of these pathways. TNBC samples showed enrichment in cell-cycle pathways (E2F, G2/M), mitochondrial dynamics, glycolysis, and inflammatory responses (CXCR4, HIF1A), aligning with the experimental GH-DRP1 axis model.

5. Significance

This study identifies the GH–DRP1 axis as a critical regulator of TNBC aggressiveness. It reveals that:

1. Mitochondrial fission is not just a structural change but a functional switch required to couple metabolic reprogramming (glycolysis) to cell-cycle progression.
2. GH acts as a metabolic integrator, utilizing DRP1 to manage stress responses (p53/HIF1A) and shape the tumor microenvironment toward a pro-inflammatory state.
3. Therapeutic Implications: Targeting mitochondrial fission (e.g., via DRP1 inhibition) could disrupt the metabolic flexibility of TNBC, potentially sensitizing tumors to stress and limiting their ability to adapt to the hypoxic microenvironment. This offers a novel strategy to counteract GH-driven tumor progression in triple-negative breast cancer.